Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01277510
Registration number
NCT01277510
Ethics application status
Date submitted
13/01/2011
Date registered
17/01/2011
Date last updated
29/06/2020
Titles & IDs
Public title
Pediatric Chronic Kidney Disease Safety and Efficacy
Query!
Scientific title
A Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis
Query!
Secondary ID [1]
0
0
20070208
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Kidney Disease
0
0
Query!
Hyperparathyroidism
0
0
Query!
Hyperparathyroidism, Secondary
0
0
Query!
Kidney Disease
0
0
Query!
Secondary Hyperparathyroidism
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Kidney disease
Query!
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other endocrine disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - cinacalcet capsule
Treatment: Drugs - placebo
Treatment: Drugs - Standard of Care
Placebo Comparator: Placebo - Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was = 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
Experimental: Cinacalcet - Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was = 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
Treatment: Drugs: cinacalcet capsule
Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
Treatment: Drugs: placebo
Placebo tablets and capsules for sprinkling identical to active treatment.
Treatment: Drugs: Standard of Care
All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving = 30% Reduction in Mean iPTH From Baseline to the Efficacy Assessment Phase
Query!
Assessment method [1]
0
0
The efficacy assessment value is based on the scheduled assessment(s) taken during the efficacy assessment phase (EAP; Weeks 25 - 30). When multiple assessments were available, the average of those was used. If an efficacy measurement during the EAP was missing, the mean of the last 2 available post-baseline values in the dose-titration phase was used. If only one post-baseline value was available, this single value was used.
Query!
Timepoint [1]
0
0
From Baseline to the Efficacy Assessment Phase, Weeks 25-30
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving Mean iPTH = 300 pg/mL (31.8 Pmol/L) During the Efficacy Assessment Phase
Query!
Assessment method [1]
0
0
The efficacy assessment value is based on the scheduled assessment(s) taken during the efficacy assessment phase. When multiple assessments were available, the average of those was used. If an efficacy measurement during the EAP was missing, the mean of the last 2 available postbaseline values in the dose-titration phase was used. If only one post-baseline value was available, this single value was used.
Query!
Timepoint [1]
0
0
From Baseline to the Efficacy Assessment Phase (EAP), Weeks 25-30
Query!
Secondary outcome [2]
0
0
Percent Change From Baseline in Mean Corrected Total Serum Calcium During the Efficacy Assessment Period
Query!
Assessment method [2]
0
0
Serum calcium was reported as a corrected value by the central laboratory based on calcium and albumin concentrations: Corrected total calcium (mg/dL) = measured total serum calcium (mg/dL) + 0.8 (4.0 - Serum albumin (g/dL)). The efficacy assessment value is based on the scheduled assessment(s) taken during the efficacy assessment phase. When multiple assessments were available, the average of those was used. If an efficacy measurement during the EAP was missing, the mean of the last 2 available postbaseline values in the dose-titration phase was used. If only one post-baseline value was available, this single value was used."
Query!
Timepoint [2]
0
0
From Baseline to the Efficacy Assessment Phase, Weeks 25-30.
Query!
Secondary outcome [3]
0
0
Percent Change From Baseline in Mean Serum Phosphorus During the Efficacy Assessment Phase
Query!
Assessment method [3]
0
0
The efficacy assessment value is based on the scheduled assessment(s) taken during the efficacy assessment phase. When multiple assessments were available, the average of those was used. If an efficacy measurement during the EAP was missing, the mean of the last 2 available postbaseline values in the dose-titration phase was used. If only one post-baseline value was available, this single value was used.
Query!
Timepoint [3]
0
0
From Baseline to the Efficacy Assessment Phase, Weeks 25-30.
Query!
Secondary outcome [4]
0
0
Percent Change From Baseline in Mean Phosphorous Product (Ca x P) During the Efficacy Assessment Phase
Query!
Assessment method [4]
0
0
The efficacy assessment value is based on the scheduled assessment(s) taken during the efficacy assessment phase. When multiple assessments were available, the average of those was used. If an efficacy measurement during the EAP was missing, the mean of the last 2 available postbaseline values in the dose-titration phase was used. If only one post-baseline value was available, this single value was used.
Query!
Timepoint [4]
0
0
From Baseline to end of Efficacy Assessment Period, assessed up to 30 weeks
Query!
Secondary outcome [5]
0
0
Growth Velocity From Baseline to End of Double-blind Phase
Query!
Assessment method [5]
0
0
Linear growth velocity (cm/year) = 52 x change in height (cm) / number of weeks between the two assessments. End of double-blind phase visit was at Week 30 by design but the last assessment in the double-blind phase was used due to the early termination of the study.
Query!
Timepoint [5]
0
0
From Baseline to end of Efficacy Assessment at Week 30
Query!
Secondary outcome [6]
0
0
Growth Velocity From End of Double-blind Phase to End of Open-label Phase
Query!
Assessment method [6]
0
0
Linear growth velocity (cm/year) = 52 x change in height (cm) / number of weeks between the two assessments. End of open-label phase visit was at Week 60 by design but the last assessment in the open-label phase was used due to the early termination of the study.
Query!
Timepoint [6]
0
0
End of double-blind phase (Week 30) until end of the open-label phase (Week 60)
Query!
Secondary outcome [7]
0
0
Percent Change From Baseline in Mean Ionized Calcium During the Efficacy Assessment Phase
Query!
Assessment method [7]
0
0
The efficacy assessment value is based on the scheduled assessment(s) taken during the efficacy assessment phase. When multiple assessments were available, the average of those was used. If an efficacy measurement during the EAP was missing, the mean of the last 2 available postbaseline values in the dose-titration phase was used. If only one post-baseline value was available, this single value was used.
Query!
Timepoint [7]
0
0
From Baseline to the Efficacy Assessment Phase, Weeks 25-30.
Query!
Eligibility
Key inclusion criteria
- Age 6 to less than 18 years at screening
- Diagnosed with CKD and SHPT receiving hemodialysis or peritoneal dialysis for = 2
months before randomization
- Dry weight = 12.5 kg at screening
- iPTH obtained from the central laboratory must be > 300 pg/mL (31.8 pmol/L)
- Serum calcium (corrected) obtained from the central laboratory must be = 8.8 mg/dL
(2.2 mmol/L)
- Serum phosphorus obtained from the central laboratory = 4.0 mg/dL (1.3 mmol/L) for
children 6 to less than 12 years old, or = 3.5 mg/dL (1.1 mmol/L) for children 12 to
less than 18 years old
- Subjects already receiving vitamin D sterols (either calcitriol or a synthetic
analog), a stable dose within the last 2 months prior to randomization
- Subjects taking growth hormone, a stable dose defined as no change > than 20% in the
last 2 months prior to randomization
- Subjects on anti-convulsant medication must be on a stable dose for 3 months, and have
a therapeutic blood level of the anti-convulsant at the time of randomization
- Subjects must be on a dialysate calcium concentration of = 2.5 mEq/L (1.25 mmol/L) for
at least 2 months prior to randomization
Query!
Minimum age
6
Years
Query!
Query!
Maximum age
17
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Underwent parathyroidectomy in the last 6 months
- Anticipated parathyroidectomy within 6 months after randomization
- Received therapy with cinacalcet (sensipar/mimpara) within the last month
- A new onset of seizure or worsening of a pre-existing seizure disorder within the last
3 months
- Scheduled date for kidney transplant from a known living donor that makes completion
of the study unlikely
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/06/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
43
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Research Site - Randwick
Query!
Recruitment hospital [2]
0
0
Research Site - Westmead
Query!
Recruitment hospital [3]
0
0
Research Site - Herston
Query!
Recruitment hospital [4]
0
0
Research Site - Parkville
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [4]
0
0
3052 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
North Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Bruxelles
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Edegem
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Gent
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Leuven
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Heidelberg
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Marburg
Query!
Country [21]
0
0
Hungary
Query!
State/province [21]
0
0
Budapest
Query!
Country [22]
0
0
Hungary
Query!
State/province [22]
0
0
Debrecen
Query!
Country [23]
0
0
Hungary
Query!
State/province [23]
0
0
Pecs
Query!
Country [24]
0
0
Hungary
Query!
State/province [24]
0
0
Szeged
Query!
Country [25]
0
0
Mexico
Query!
State/province [25]
0
0
Distrito Federal
Query!
Country [26]
0
0
Mexico
Query!
State/province [26]
0
0
Aguascalientes
Query!
Country [27]
0
0
Poland
Query!
State/province [27]
0
0
Gdansk
Query!
Country [28]
0
0
Poland
Query!
State/province [28]
0
0
Gorzow Wielkopolski
Query!
Country [29]
0
0
Poland
Query!
State/province [29]
0
0
Lodz
Query!
Country [30]
0
0
Poland
Query!
State/province [30]
0
0
Warszawa
Query!
Country [31]
0
0
Russian Federation
Query!
State/province [31]
0
0
Moscow
Query!
Country [32]
0
0
Russian Federation
Query!
State/province [32]
0
0
Saint Petersburg
Query!
Country [33]
0
0
Russian Federation
Query!
State/province [33]
0
0
Samara
Query!
Country [34]
0
0
Slovakia
Query!
State/province [34]
0
0
Banska Bystrica
Query!
Country [35]
0
0
Slovakia
Query!
State/province [35]
0
0
Bratislava
Query!
Country [36]
0
0
Slovakia
Query!
State/province [36]
0
0
Kosice
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Cataluña
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Cataluña
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Comunidad Valenciana
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
PaÃ-s Vasco
Query!
Country [41]
0
0
Spain
Query!
State/province [41]
0
0
País Vasco
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Madrid
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety and efficacy of adding cinacalcet to the
current treatment of secondary hyperparathyroidism in children currently receiving dialysis
compared to a treatment regimen that does not include cinacalcet.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01277510
Query!
Trial related presentations / publications
Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, Laskin B, Shahinfar S, Vande Walle J, Schaefer F. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol. 2019 Mar;34(3):475-486. doi: 10.1007/s00467-018-4116-y. Epub 2018 Nov 30.
Warady BA, Ng E, Bloss L, Mo M, Schaefer F, Bacchetta J. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol. 2020 Sep;35(9):1679-1697. doi: 10.1007/s00467-020-04516-4. Epub 2020 May 4.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01277510
Download to PDF